Logo Image

Erik Wiklund

Erik Wiklund

Erik Digman Wiklund is CEO of Circio. He has deep scientific knowledge in RNA and cancer biology and 13 years of pharma and biotech industry experience in a variety of functions including R&D, finance and business development. Wiklund holds a PhD in molecular biology from Aarhus University in Denmark and the Garvan Institute of Medical Research in Sydney, Australia.

Articles by Erik Wiklund

Erik Wiklund, CEO of Circio, discusses circular RNA technology and next-generation AAV gene therapy platforms at ASGCT 2026 in Boston.

Circio CEO Highlights Circular RNA Potential for Safer, More Efficient Gene Therapy

ByEmily Schoenthaler,Erik Wiklund
Published: | Updated:

Circio CEO Erik Wiklund discussed how circular RNA technology may improve the safety, durability, and cost-efficiency of AAV gene therapies for cardiovascular diseases at ASGCT 2026. Early animal data suggest the platform reduces cellular stress responses while increasing gene expression, potentially expanding access to safer and more scalable gene therapy treatments.

Latest Updated Articles